Latest Insider Transactions at Apellis Pharmaceuticals, Inc. (APLS)
This section provides a real-time view of insider transactions for Apellis Pharmaceuticals, Inc. (APLS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Apellis Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Apellis Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 15
2021
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.37%
|
$5,000
$2.67 P/Share
|
|
Jan 14
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,000
-10.04%
|
$204,000
$51.99 P/Share
|
|
Jan 04
2021
|
Nicole D Perry Vice President - Accounting |
SELL
Open market or private sale
|
Direct |
2,000
-100.0%
|
$114,000
$57.24 P/Share
|
|
Jan 04
2021
|
Nicole D Perry Vice President - Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$6,000
$3.76 P/Share
|
|
Jan 04
2021
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
600
-1.48%
|
$34,200
$57.24 P/Share
|
|
Dec 23
2020
|
Jeffrey Eisele Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,211
+50.0%
|
-
|
|
Dec 15
2020
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-0.45%
|
$260,000
$52.16 P/Share
|
|
Dec 15
2020
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
2,500
-0.37%
|
$130,000
$52.16 P/Share
|
|
Dec 15
2020
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.37%
|
$5,000
$2.67 P/Share
|
|
Dec 14
2020
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
25,000
-4.29%
|
$1,375,000
$55.04 P/Share
|
|
Dec 14
2020
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
8,398
-2.89%
|
$445,094
$53.24 P/Share
|
|
Dec 14
2020
|
David O. Watson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
8,398
+13.95%
|
$109,174
$13.85 P/Share
|
|
Dec 11
2020
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
9,935
-18.63%
|
$496,750
$50.0 P/Share
|
|
Dec 11
2020
|
David O. Watson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
9,935
+15.7%
|
$129,155
$13.85 P/Share
|
|
Dec 08
2020
|
Lukas Scheibler Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,482
+26.65%
|
$194,532
$26.73 P/Share
|
|
Dec 07
2020
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
18,564
-4.35%
|
$928,200
$50.71 P/Share
|
|
Dec 04
2020
|
Federico Grossi Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,250
+15.21%
|
$21,750
$3.2 P/Share
|
|
Dec 04
2020
|
Nicole D Perry Vice President - Accounting |
SELL
Open market or private sale
|
Direct |
18,000
-100.0%
|
$900,000
$50.0 P/Share
|
|
Dec 04
2020
|
Nicole D Perry Vice President - Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
18,000
+50.0%
|
$54,000
$3.76 P/Share
|
|
Dec 04
2020
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
6,436
-1.44%
|
$321,800
$50.55 P/Share
|
|
Dec 01
2020
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
600
-1.78%
|
$28,800
$48.25 P/Share
|
|
Dec 01
2020
|
Cedric Francois Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+3.45%
|
$120,000
$3.76 P/Share
|
|
Nov 16
2020
|
Federico Grossi Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,750
+14.55%
|
$17,250
$3.2 P/Share
|
|
Nov 16
2020
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
2,500
-0.37%
|
$97,500
$39.38 P/Share
|
|
Nov 16
2020
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.37%
|
$5,000
$2.67 P/Share
|
|
Nov 16
2020
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-0.46%
|
$195,000
$39.38 P/Share
|
|
Nov 02
2020
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
600
-2.12%
|
$18,600
$31.09 P/Share
|
|
Oct 15
2020
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,000
-0.46%
|
$170,000
$34.46 P/Share
|
|
Oct 15
2020
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
2,500
-0.37%
|
$87,500
$35.0 P/Share
|
|
Oct 15
2020
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+0.37%
|
$5,000
$2.67 P/Share
|
|
Oct 07
2020
|
Victoria L. Brown Program Team Lead |
SELL
Open market or private sale
|
Direct |
12,000
-76.89%
|
$420,000
$35.0 P/Share
|
|
Oct 07
2020
|
Victoria L. Brown Program Team Lead |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+43.47%
|
$216,000
$18.98 P/Share
|
|
Oct 07
2020
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
7,500
-1.11%
|
$262,500
$35.0 P/Share
|
|
Oct 07
2020
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+1.1%
|
$15,000
$2.67 P/Share
|
|
Oct 01
2020
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
600
-2.07%
|
$18,000
$30.22 P/Share
|
|
Nov 13
2017
|
Cormorant Asset Management, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,071,428
+23.57%
|
$14,999,992
$14.0 P/Share
|
|
Nov 13
2017
|
Cormorant Asset Management, LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,402,497
+50.0%
|
-
|
|
Nov 13
2017
|
Aju Ib Investment Co., Ltd. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,292,062
+50.0%
|
-
|